Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Ameluz for Actinic Keratosis

Biofrontera news release; 2016 May 11

The FDA has approved Ameluz (aminolevulinic acid hydrochloride; Biofrontera) gel, for the treatment of mild-to-moderate actinic keratosis (AK) on the face and scalp.

Indications: Ameluz gel is a porphyrin precursor, which is used in combination with photodynamic therapy using the BF-RhodoLED lamp. It is indicated for lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp.

Dosage/administration: Each gram of Ameluz gel 10% contains 100 mg of aminolevulinic acid hydrochloride (equivalent to 78 mg of aminolevulinic acid). Ameluz gel is to be administered by a health care provider and is for topical use only. Photodynamic therapy with Ameluz involves preparation of lesions, application of the product, and occlusion and illumination with BF-RhodoLED. Lesions that have not completely resolved 3 months after the initial treatment should be retreated.

Adverse reactions: The most common adverse reactions (≥10%) were application site erythema, pain/burning, irritation, edema, pruritis, exfoliation, scab, induration, and vesicles.

Citation: Biofrontera announces US FDA approval of Ameluz and activating BF-RhodoLED device for treatment of actinic keratosis. [news release]. Leverkusen, Germany: Biofrontera; May 11, 2016: www.biofrontera.com. Accessed May 11, 2016.

This Week's Must Reads

Racial/Ethnic Differences in Childhood Eczema Care, J Am Acad Dermatol; 2017 Dec; Fischer, et al

Eczema Herpeticum Hospitalizations Increase Noted, J Invest Dermatol; ePub 2017 Sep 16; Hsu, Shinkai, et al

Atopic Dermatitis Linked with Hand Eczema, Br J Dermatol; ePub 2017 Nov 24; Ruff, et al

EAPs Aid Patients with Limited Health Literacy , J Cutan Med Surg; ePub 2017 Nov 3; McEvoy, et al

Phenotypical Differences of Adult, Childhood AD, J Allergy Clin Immunol; ePub 2017 Nov 10; Silverberg, et al

Must Reads in Actinic Keratosis

Cost of Managing AK Varies by Region, JAMA Dermatol; ePub 2017 Mar 1; Kirby, et al

Physician Wording Role in Seeking AK Treatment, JAMA Dermatol; ePub 2017 Jan 18; Berry, Butt, et al

Acantholysis in SCC Not Considered High Risk, J Am Acad Dermatol; ePub 2016 Nov 23; Ogawa, et al

Prevalence of Nonmelanoma Skin Cancers High in VHA, Dermatol Surg; ePub 2016 Jul 25; Yoon, Phibbs, et al

FDA Approves Ameluz for Actinic Keratosis, Biofrontera news release; 2016 May 11